2646703-64-0
Chemical Structure
Zerlasiran
Synonym(s): SLN360
- CAS No.: 2646703-64-0
- Formula:C443H594N144O277P40S10
- Molecular Weight:14155.81
IUPAC Name: N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-7-(1-((1-(4-(4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)but-3-yn-1-yl)piperazine-1-carbonyl)piperazin-1-yl)-4-oxobutanoyl)piperidin-4-yl)methyl)-3-methyl-1H-indol-5-yl)-4-oxo-5-propyl-4,5-dihydrothieno[3,2-c]pyridine-2-carboxamide
SMILES: [Zerlasiran]
Biological Activity: Zerlasiran (SLN360) is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zerlasiran | Zerlasiran (SLN360) is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Nissen SE, et al. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2024 May 14;331(18):1534-1543. [Content Brief]
- [2]. Fazoli RT, et al. RNA interference therapy in cardiology: will new targets improve therapeutic goals?. Drugs Context. 2024;13:2024-3-1. Published 2024 Aug 20. [Content Brief]
Keywords
